Eli Marom
Overview
Explore the profile of Eli Marom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R, et al.
J Clin Pharmacol
. 2017 Feb;
57(7):823-829.
PMID: 28181259
No abstract available.
12.
Israel S, Maggio N, Ekstein D, Zaid H, Firer M, Bederovsky Y, et al.
Epilepsia
. 2016 Aug;
57(10):e205-e209.
PMID: 27527795
The human leukocyte antigen (HLA) alleles B*15:02 and A*31:01 have been identified as predictive markers of adverse cutaneous effects of carbamazepine and phenytoin in Asian and North European populations, respectively....
13.
Berman E, Marom E, Ekstein D, Blatt I, Eyal S
Epilepsy Behav
. 2016 Jun;
61:82-85.
PMID: 27344499
Purpose: The aim of the study was to identify trends in utilization of antiepileptic drugs (AEDs) over time in a nation-wide population in Israel. Methods: Data on AED utilization (for...
14.
Ponizovsky A, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E
Isr J Health Policy Res
. 2016 Jun;
5:16.
PMID: 27307984
Background: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this...
15.
Ponizovsky A, Marom E, Fitoussi I
Pharmacoepidemiol Drug Saf
. 2014 Mar;
23(5):534-8.
PMID: 24610676
Purpose: The aim of this study was to describe trends in attention deficit hyperactivity disorder (ADHD) drugs consumption in Israel (Ritalin, Concerta, Daytrana, Vyvanse, Focalin, and Adderall) over the 8 ...
16.
Berkovitz R, Arieli M, Marom E
Harefuah
. 2012 Feb;
150(12):884-7, 937.
PMID: 22352277
Recently, a new Law, named the "derivative law" (first addition, schedule drug change--2010), was accepted in the Israeli parliament. It will mean that dangerous substances that are closely related structurally...
17.
Ponizovsky A, Pchelintsev M, Marom E, Zvartau E
Eur J Clin Pharmacol
. 2011 Jul;
68(1):89-95.
PMID: 21792563
Objective: To compare trends in opioid consumption in Israel and St. Petersburg/Russia (morphine, oxycodone, pethidine, fentanyl, methadone, buprenorphine, trimeperidine, and papaveretum) over the period 2000-2008, and to describe the regulatory...
18.
Furman-Assaf S, Tamir O, Marom E, Arieli M, Shemer J
Harefuah
. 2011 Apr;
149(7):470-5, 479.
PMID: 21465764
Counterfeit drugs are a major threat to public health and safety around the world. This review describes the various distribution methods and channels of counterfeit drugs, including the growing use...
19.
Tamir O, Friedman N, Furman-Assaf S, Marom E, Arieli M, Shemer J
Harefuah
. 2011 Apr;
149(7):466-9, 479.
PMID: 21465763
A counterfeit drug is one which is deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeit drugs can be found worldwide, both in deveLoped and developing countries, and...
20.
Abadi-Korek I, Vaknin S, Marom E, Shemer J, Luxenburg O
Harefuah
. 2011 Apr;
150(1):29-32, 69, 68.
PMID: 21449153
The reformation in the marketing of non-prescription medicinal products has been launched. As of May 10th 2005, the pharmacist regulations 2004 (marketing of over-the-counter (OTC) drugs outside of pharmacies, as...